SuperworthAnixa Biosciences market cap ANIX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $103.9M
- Highest close in our data
- $186.1M
- Mar 2021
Anixa Biosciences is worth $103.9M at the close on Oct 23, 2026, at $2.99 a share.
That is down 24% over the last year and down 27% over five years.
Its highest close in our data was $186.1M in Mar 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $103.9M | $83.1M | $126.2M | −1% |
| 2025 | $105.3M | $72.4M | $157.7M | +28% |
| 2024 | $82.4M | $70.7M | $157.2M | −32% |
| 2023 | $120.6M | $91M | $184.6M | −7% |
| 2022 | $130.3M | $77.5M | $175.1M | +46% |
| 2021 | $89M | $89M | $186.1M | +22% |
| 2020 | $73M | $28.4M | $80.4M | +25% |
| 2019 | $58.4M | $56.2M | $104.4M | −22% |
| 2018 | $74.8M | $40.4M | $112.6M | +110% |
| 2017 | $35.7M | $8.3M | $48.2M | −24% |
| 2016 | $47.3M | $16.4M | $59M | +80% |
| 2015 | $26.3M | $15.4M | $51.4M | −7% |
| 2014 | $28.2M | $26M | $84.2M | −29% |
| 2013 | $39.4M | $37M | $65.2M | +26% |
| 2012 | $31.4M | $14.6M | $59.2M | +64% |
| 2011 | $19.2M | $19.2M | $29.7M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Anixa Biosciences' size, closest first, today.
| Company | Market cap |
|---|---|
| ANIXAnixa Biosciences | $103.9M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| NATRNatures Sunshine Products | $213.8M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Anixa Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.